https://www.selleckchem.com/products/px-12.html
Paclitaxel (taxol), a chemotherapeutic agent, remains the standard of care for the lethal triple-negative breast cancer (TNBC). However, over 50% of TNBC patients become resistant to chemotherapy and, to date, no solution is available. CR6-interacting factor 1 (CRIF1) is reported to act as a negative regulator of the cell cycle by interacting with cyclin-dependent kinase 2 (CDK2). In our study, two selective CRIF1-CDK2 interface inhibitors were used to investigate whether they could exert anti-proliferative activity on the TNBC cell lines
Like
Comment
Share
